ConfavreuxCVukusicSMoreauT. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–1438.
2.
SawcerSHellenthalGPirinenM. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature2011; 476: 214–219.
3.
KutzelniggALucchinettiCFStadelmannC. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain2005; 128: 2705–2712.
4.
HawkerKO’ConnorPFreedmanMS. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66: 460–471.
5.
LucchinettiCBrückWParisiJ. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol2000; 47: 707–717.
6.
IngleGTStevensonVLMillerDH. Primary progressive multiple sclerosis: A 5-year clinical and MR study. Brain2003; 126: 2528–2536.
7.
LucchinettiCFPopescuBFBunyanRF. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med2011; 365: 2188–2197.
8.
ChoiSRHowellOWCarassitiD. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain2012; 135: 2925–2937.
9.
KolasinskiJStaggCJChanceSA. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain2012; 135: 2938–2951.
10.
SimonJHKinkelRPJacobsL. A Wallerian degeneration pattern in patients at risk for MS. Neurology2000; 54: 1155–1160.
11.
TallantyreECBoLAl-RawashdehO. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain2009; 132: 1190–1199.
12.
KuhlmannTLingfeldGBitschA. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain2002; 125: 2202–2212.
